Calcineurin A-binding protein, a novel modulator of the calcineurin-nuclear factor of activated T-cell signaling pathway, is overexpressed in Wilms' tumors and promotes cell migration

Molecular Cancer Research

Volumn 7, Issue 6, 2009, Pages 821-831

  Nguyen, Alana H T ^a   Béland, Mélanie ^a   Gaitan, Yaned ^a   Bouchard, Maxime ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN A BINDING PROTEIN; CALCINEURIN ABETA; CALCINEURIN PHOSPHATASE; PHOSPHATASE; SERINE; THREONINE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR PAX2; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SEQUENCE; GENE STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY DEVELOPMENT; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANIMALS; CALCINEURIN; CELL GROWTH PROCESSES; CELL LINE; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED C3H; MOLECULAR SEQUENCE DATA; NFATC TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; PHOSPHOPROTEINS; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; WILMS TUMOR;

VERTEBRATA;

EID: 67649631302     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0402     Document Type: Article

References (64)

1. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005;5:699-712. (Pubitemid 41486363)
2. Li CM, Guo M, Borczuk A, et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002;160:2181-2190 (Pubitemid 34663409)
3. Jones KP, Grundy PE, Coppes MJ. Recent advances in the genetics of childhood renal cancers: a report of the 3rd International Conference on the molecular and clinical genetics of childhood renal tumors, together with the Mitchell Ross symposium on anaplastic and other high risk embryonal tumors of childhood, 8-10th April 1999, Wistar Institute, Philadelphia, PA. Med Pediatr Oncol 2000;35:126-130
4. Grundy P, Breslow N, Green DM, Sharples K, Evans A, D'Angio GJ. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989;7:638-647 (Pubitemid 19126801)
5. Bonadio JF, Storer B, Norkool P, Farewell VT, Beckwith JB, D' Angio GJ. Anaplastic Wilms' tumor: clinical and pathologic studies. J Clin Oncol 1985;3:513-520 (Pubitemid 15111399)
6. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 1978;41:1937-1948 (Pubitemid 8335406)
7. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994;54:2331-2333 (Pubitemid 24138720)
8. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 1998;78:1181-1187 (Pubitemid 28479148)
9. Li W, Kessler P, Yeger H, et al. A gene expression signature for relapse of primary Wilms tumors. Cancer Res 2005;65:2592-2601 (Pubitemid 40490057)
10. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-520 (Pubitemid 20060879)
11. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990;343:774-778 (Pubitemid 20065258)
12. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990;61:1257-1269 (Pubitemid 20208830)
13. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991;67:437-447 (Pubitemid 121001458)
14. Varanasi R, Bardeesy N, Ghahremani M, et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci U S A 1994;91:3554-3558 (Pubitemid 24139468)
15. Kikuchi H, Akasaka Y, Nagai T, et al. Genomic changes in the WT-gene (WT1) in Wilms' tumors and their correlation with histology. Am J Pathol 1992;140:781-786
16. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell 1993;74:679-691 (Pubitemid 23259748)
17. Donovan MJ, Natoli TA, Sainio K, et al. Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud. Dev Genet 1999;24:252-262 (Pubitemid 29211789)
18. Davies JA, Ladomery M, Hohenstein P, et al. Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet 2004;13:235-246 (Pubitemid 38111361)
19. Dressler GR, Douglass EC. Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci U S A 1992;89:1179-1183
20. Poleev A, Fickenscher H, Mundlos S, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 1992;116:611-623
21. Eccles MR, Yun K, Reeve AE, Fidler AE. Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors. Am J Pathol 1995;146:40-45
22. Ryan G, Steele-Perkins V, Morris JF, Rauscher F, Jr., Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. Development 1995;121:867-875
23. Dehbi M, Ghahremani M, Lechner M, Dressler G, Pelletier J. The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene 1996;13:447-453 (Pubitemid 26283840)
24. Brophy PD, Ostrom L, Lang KM, Dressler GR. Regulation of ureteric bud outgrowth by Pax2-dependent activation of the glial derived neurotrophic factor gene. Development 2001;128:4747-4756 (Pubitemid 33138585)
25. Narlis M, Grote D, Gaitan Y, Boualia SK, Bouchard M. Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol 2007;18:1121-1129 (Pubitemid 46536898)
26. Gnarra JR, Dressler GR. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 1995;55:4092-4098
27. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003;22:7989-7997 (Pubitemid 37179944)
28. Hueber PA, Waters P, Clark P, Eccles M, Goodyer P. PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int 2006;69:1139-1145
29. Fonsato V, Buttiglieri S, Deregibus MC, Puntorieri V, Bussolati B, Camussi G. Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 2006;168:706-713 (Pubitemid 43271166)
30. Ostrom L, Tang MJ, Gruss P, Dressler GR. Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol 2000;219:250-258 (Pubitemid 30152603)
31. Porteous S, Torban E, Cho NP, et al. Primary renal hypoplasia in humans and mice with PAX2 mutations: evidence of increased apoptosis in fetal kidneys of Pax2(1Neu) +/- mutant mice. Hum Mol Genet 2000;9:1-11. (Pubitemid 30145283)
32. Torban E, Eccles MR, Favor J, Goodyer PR. PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 2000;157:833-842 (Pubitemid 32109376)
33. Bouchard M, Pfeffer P, Busslinger M. Functional equivalence of the transcription factors Pax2 and Pax5 in mouse development. Development 2000;127:3703-3713
34. Buttiglieri S, Deregibus MC, Bravo S, et al. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem 2004;279:4136-4143 (Pubitemid 38198998)
35. Igarashi T, Ueda T, Suzuki H, et al. Aberrant expression of Pax-2 mRNA in renal cell carcinoma tissue and parenchyma of the affected kidney. Int J Urol 2001;8:60-64 (Pubitemid 32245344)
36. Grote D, Souabni A, Busslinger M, Bouchard M. Pax2/8-regulated Gata3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 2006;133:53-61. (Pubitemid 43169320)
37. Gaitan Y, Bouchard M. Expression of the δ-protocadherin gene Pcdh19 in the developing mouse embryo. Gene Expr Patterns 2006;6:893-899 (Pubitemid 44309440)
38. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr Opin Pediatr 2002;14:5-11. (Pubitemid 34169564)
39. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512 (Pubitemid 28425575)
40. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-697
41. Zaninetti R, Tacchi S, Erriquez J, et al. Calcineurin primes immature GnRH-secreting neuroendocrine cells for migration. Mol Endocrinol 2007.
42. 2+/ calcineurin/NFAT signaling in cancerogenesis. Cell Cycle 2007;6:16-19
43. 2+/calcineurin signaling pathway. EMBO J 2006;25:3714-3724
44. Eckstein LA, Van Quill KR, Bui SK, Uusitalo MS, O'Brien JM. Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci 2005;46:782-790 (Pubitemid 41321012)
45. Corral RS, Iniguez MA, Duque J, Lopez-Perez R, Fresno M. Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. Oncogene 2007;26:958-969 (Pubitemid 46272206)
46. Tagge EP, Hanson P, Re GG, Othersen HB, Jr., Smith CD, Garvin AJ. Paired box gene expression in Wilms' tumor. J Pediatr Surg 1994;29:134-141 (Pubitemid 24068614)
47. Eccles MR, Wallis LJ, Fidler AE, Spurr NK, Goodfellow PJ, Reeve AE. Expression of the PAX2 gene in human fetal kidney and Wilms' tumor. Cell Growth Differ 1992;3:279-289
48. Charles AK, Brown KW, Berry PJ. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. Am J Pathol 1998;153:991-1000. (Pubitemid 28419052)
49. Tendron A, Decramer S, Justrabo E, Gouyon JB, Semama DS, Gilbert T. Cyclosporin A administration during pregnancy induces a permanent nephron deficit in young rabbits. J Am Soc Nephrol 2003;14:3188-3196 (Pubitemid 37509294)
50. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine- associated chronic nephropathy. N Engl J Med 1984;311:699-705. (Pubitemid 14074555)
51. Glud SZ, Sorensen AB, Andrulis M, et al. A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood 2005;106:3546-3552 (Pubitemid 41609192)
52. Lee H, Chouinard L, Bonin M, Michel RN. NFATc3 deficiency may contribute to the development of mammary gland adenocarcinoma in aging female mice. Mol Carcinog 2005;44:219-222 (Pubitemid 41552755)
53. Baksh S, Widlund HR, Frazer-Abel AA, et al. NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell 2002;10:1071-1081 (Pubitemid 35453825)
54. Czirjak G, Enyedi P. Targeting of calcineurin to an NFAT-like docking site is required for the calcium-dependent activation of the background K+ channel, TRESK. J Biol Chem 2006;281:14677-14682 (Pubitemid 43855172)
55. Aramburu J, Garcia-Cozar F, Raghavan A, Okamura H, Rao A, Hogan PG. Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol Cell 1998;1:627-637 (Pubitemid 128379241)
56. Lai MM, Burnett PE, Wolosker H, Blackshaw S, Snyder SH. Cain, a novel physiologic protein inhibitor of calcineurin. J Biol Chem 1998;273:18325-18331 (Pubitemid 28334757)
57. Miskin JE, Abrams CC, Dixon LK. African swine fever virus protein A238L interacts with the cellular phosphatase calcineurin via a binding domain similar to that of NFAT. J Virol 2000;74:9412-9420 (Pubitemid 30746790)
58. Sun L, Youn HD, Loh C, Stolow M, He W, Liu JO. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 1998;8:703-711 (Pubitemid 28294517)
59. Li H, Zhang L, Rao A, Harrison SC, Hogan PG. Structure of calcineurin in complex with PVIVIT peptide: portrait of a low-affinity signalling interaction. J Mol Biol 2007;369:1296-1306 (Pubitemid 46770774)
60. Henrique D, Adam J, Myat A, Chitnis A, Lewis J, Ish-Horowicz D. Expression of a Delta homologue in prospective neurons in the chick. Nature 1995;375:787-790
61. Bouchard M, Souabni A, Mandler M, Neubuser A, Busslinger M. Nephric lineage specification by Pax2 and Pax8. Genes Dev 2002;16:2958-2970 (Pubitemid 35334743)
62. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 1991;11:1707-1712 (Pubitemid 21895530)
63. Kunz F, Shalaby T, Lang D, et al. Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology 2006;26:393-399 (Pubitemid 44454408)
64. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006;66:1313-1319 (Pubitemid 43259909)